Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.

Leigh PerreaultMelanie DaviesJuan Pablo FriasPeter Nørkjaer LaursenIldiko LingvaySriram MachineniAnette VarboJohn P H WildingSigne Olrik Rytter WallensteinCarel W le Roux

Published in: Diabetes care (2022)

STEP 1, 3, and 4 collectively provide a robust assessment of the effects of semaglutide on glucose metabolism and prediabetes in a large cohort of adults with overweight/obesity while on treatment. Among participants with baseline prediabetes, 68 weeks' treatment with semaglutide versus placebo led to significant improvements in glucose metabolism and a higher likelihood of normoglycemia.

Keyphrases

type diabetes
weight loss
metabolic syndrome
insulin resistance
randomized controlled trial
combination therapy
body mass index
skeletal muscle
preterm birth